Myelodysplastic syndromes are a diverse and common group of chronic hematologic cancers. The identification of new genetic lesions could facilitate new diagnostic and therapeutic strategies. We used ...

You have full access to this article via your institution. For each patient, demographic (gender and age at diagnosis) and biological data (blood cell count, bone marrow exploration, ring sideroblasts ...

You have full access to this article via your institution. Eight (10%) patients had a thrombotic event prior to or at the time of diagnosis of RARS-T (venous-8, arterial-0). Nine (11%) patients ...

Sideroblastic anemia was found in an elderly man in association with dermal photosensitivity, a greatly increased erythrocyte free protoporphyrin content and reduced erythrocyte catalase activity.

Dear Dr. Roach: I am 92 and consider myself very fortunate, health-wise. In the middle of the 1980s, I was diagnosed with Sideroblastic anemia. My doctor in Florida did many tests to make the ...

Dear Dr. Roach: I am 92 and consider myself very fortunate, health-wise. In the middle of the 1980s, I was diagnosed with sideroblastic anemia. My doctor in Florida did many tests to make the ...

A phase I, open-label, dose-escalation study to evaluate the safety, pharmacokinetics, and pharmacodynamics of oral azacitidine in subjects with myelodysplastic syndromes (MDS) or acute myelogenous ...

The FDA has approved Reblozyl® (luspatercept–aamt; Bristol-Myers Squibb and Acceleron) for the treatment of anemia in adults with lower-risk myelodysplastic syndromes. The Food and Drug Administration ...